Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | CES2 | O00748 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28533849 | 0.78 | ALDH1A1 (0.40) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL4520085 | 0.75 | TDP1 (0.45) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL554490 | 0.74 | RAB9A (0.59) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL13243496 | 0.74 | ALDH1A1 (0.41) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL1388162 | 0.73 | ALDH1A1 (0.43) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL27945653 | 0.73 | ALDH1A1 (0.43) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL27558616 | 0.73 | TDP1 (0.46) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL8674570 | 0.71 | CES2 (0.54) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL11279520 | 0.70 | DEGS1 (0.41) | ALDH1A1CES1CES2MAPK1TDP1 | |
| SCHEMBL11279517 | 0.70 | DEGS1 (0.41) | ALDH1A1CES1CES2MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (GB) | 2010-01-28 | — | — | US | claimed |
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (SE) | 2009-09-17 | — | — | US | claimed |
| EP-2069330-A1 | 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | claimed |
| EP-2064203-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | claimed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032041-A1 | PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST PI3K ENZYMES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032028-A1 | 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032091-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | claimed |
| WO-2007066102-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | claimed |
| WO-2007066099-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | claimed |
| WO-2007066103-A1 | PYRIMIDINE DERIVATIVES AS CLASS I PI3K INHIBITOR | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | claimed |
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (GB) | 2010-01-28 | — | — | US | disclosed |
| CN-101595103-A | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | CN | disclosed |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | disclosed |
| US-6147083-A | NOVEL SUBSTITUTED 1,2-ETHANEDIAMINE DERIVATIVES WHICH ANTAGONIZE THE PHARMACOLOGICAL ACTIONS OF THE ENDOGENOUS NEUROPEPTIDE TACHYKININS KNOWN AS NEUROKININS, USEFUL FOR THE TREATMENT OF ASTHMA, ETC. | ZENECA LIMITED (GB) | 2000-11-14 | — | — | US | disclosed |
| US-5998444-A | ANTIASTHMA AGENTS; NEUROKININ ANTAGONIST | ZENECA LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| US-5710169-A | NEUROKININ ANTAGONISTS; ANTIHISTAMINES, BRONCHODILATOR AGENTS; ASTHMA | ZENECA LIMITED (GB) | 1998-01-20 | — | — | US | disclosed |
| EP-0709375-A2 | Therapeutic heterocycles | ZENECA LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | ALDH1A1 2256/4885CES1 4516/4885CES2 4785/4885 |
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MTOR, PIK3CA, PIK3CD | ALDH1A1 2727/4885CES1 4422/4885CES2 4734/4885 |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | TYMP, DPYD, TYMS | ALDH1A1 717/4885CES1 2661/4885CES2 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.